Vermont Center for Behavior and Health, Lerner School of Medicine, University of Vermont, 1 South Prospect Street, Burlington, VT 05733, USA; Integrated Substance Abuse Programs, Geffen School of Medicine, University of California at Los Angeles, 11075 Santa Monica Blvd., Ste. 200, Los Angeles, CA 90025, USA.
GreenField Health, Portland, OR, USA; School of Medicine, Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, CB669, Portland, OR 97239, USA.
Prev Med. 2019 Nov;128:105785. doi: 10.1016/j.ypmed.2019.105785. Epub 2019 Jul 27.
In 2013, Vermont leaders implemented the "hub-and-spoke" (H & S) system to increase access to medication treatment for opioid use disorder (MOUD). "Hubs" are licensed specialty opioid treatment programs (OTPs) with the authority to dispense buprenorphine/naloxone and methadone. "Spokes" are primary care practices that provide office-based opioid treatment, primarily with buprenorphine/naloxone. This report describes the qualitative component of an evaluation of the H&S system, conducted in 2016. The qualitative data collection assessed patient perspectives about the positive and negative aspects of treatment in the H & S system. The data collected included 80 responses to five open-ended questions and 24 in-depth interviews. Five open-ended questions were completed with hub (n = 40) and spoke (n = 40) participants. In-depth qualitative interviews were conducted with different hub (n =12) and spoke (n =12) participants. Findings from both data collection approaches suggest positive perceptions about treatment overall by patients treated in both settings. Participants treated in spokes reported a positive treatment environment, minimal stigma, and few obstacles to treatment and a strong positive relationship with their prescriber. Hub patients valued the MOUD and expressed gratitude for having access to MOUD, but reported the treatment environment was somewhat challenging, with long lines and drug talk in the clinic, high staff turnover and "cookie cutter" treatment. There appear to be some differences in patient perceptions of MOUD treatment between patients treated in primary care settings and specialized OTP settings.
2013 年,佛蒙特州的领导人实施了“枢纽-辐射”(H & S)系统,以增加阿片类药物使用障碍(MOUD)药物治疗的可及性。“枢纽”是具有分发丁丙诺啡/纳洛酮和美沙酮权限的持牌专科阿片类药物治疗计划(OTP)。“辐射”是提供基于办公室的阿片类药物治疗的初级保健实践,主要使用丁丙诺啡/纳洛酮。本报告描述了 2016 年对 H & S 系统进行的评估的定性部分。定性数据收集评估了患者对 H & S 系统中治疗的积极和消极方面的看法。收集的数据包括对五个开放式问题的 80 个回复和 24 次深度访谈。枢纽(n = 40)和辐射(n = 40)参与者完成了五个开放式问题。对不同的枢纽(n = 12)和辐射(n = 12)参与者进行了深入的定性访谈。两种数据收集方法的结果均表明,接受治疗的患者对治疗总体持积极态度。在辐射环境中接受治疗的参与者报告说,治疗环境良好,耻辱感极小,治疗障碍很少,与他们的处方者关系非常积极。枢纽患者重视 MOUD,并对获得 MOUD 表示感谢,但报告说治疗环境有些挑战,诊所里有长队和毒品谈话、高员工流动率和“一刀切”的治疗。在接受初级保健环境和专门的 OTP 环境治疗的患者中,患者对 MOUD 治疗的看法似乎存在一些差异。